• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice

tetano

Editor, Senior Moderator
Vaccine. 2016 Sep 2. pii: S0264-410X(16)30757-5. doi: 10.1016/j.vaccine.2016.08.061. [Epub ahead of print]
[h=1]M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.[/h] Sarawar S[SUP]1[/SUP], Hatta Y[SUP]2[/SUP], Watanabe S[SUP]3[/SUP], Dias P[SUP]1[/SUP], Neumann G[SUP]3[/SUP], Kawaoka Y[SUP]4[/SUP], Bilsel P[SUP]5[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Despite the annual public health burden of seasonal influenza and the continuing threat of a global pandemic posed by the emergence of highly pathogenic/pandemic strains, conventional influenza vaccines do not provide universal protection, and exhibit suboptimal efficacy rates, even when they are well matched to circulating strains. To address the need for a highly effective universal influenza vaccine, we have developed a novel M2-deficient single replication vaccine virus (M2SR) that induces strong cross-protective immunity against multiple influenza strains in mice. M2SR is able to infect cells and expresses all viral proteins except M2, but is unable to generate progeny virus. M2SR generated from influenza A/Puerto Rico/8/34 (H1N1) protected mice against lethal challenge with influenza A/Puerto Rico/8/34 (H1N1, homosubtypic) and influenza A/Aichi/2/1968 (H3N2, heterosubtypic). The vaccine induced strong systemic and mucosal antibody responses of both IgA and IgG classes. Strong virus-specific T cell responses were also induced. Following heterologous challenge, significant numbers of IFN-γ-producing CD8 T cells, with effector or effector/memory phenotypes and specific for conserved viral epitopes, were observed in the lungs of vaccinated mice. A substantial proportion of the CD8 T cells expressed Granzyme B, suggesting that they were capable of killing virus-infected cells. Thus, our data suggest that M2-deficient influenza viruses represent a promising new approach for developing a universal influenza vaccine.
Copyright ? 2016. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] CD8 T cell; Granzyme B; IFN-γ; M2-deficient; Mucosal antibody; Single replication; Sterilizing immunity; Universal influenza vaccine

PMID: 27595896 DOI: 10.1016/j.vaccine.2016.08.061
[PubMed - as supplied by publisher]
 
Back
Top Bottom